Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Pear Therapeutics is raising $111,999,925.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Corey Mccann played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pear Therapeutics

We operate at the intersection of biology and software technology, where researchers and clinicians work side-by-side with software engineers and developers to create the next generation of therapeutics. Pear Therapeutics discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions.

To learn more about Pear Therapeutics, visit http://www.peartherapeutics.com/

Contact:
Corey Mccann, President and Chief Executive Officer
617-925-7848
cmccann@peartherapeutics.com
https://www.linkedin.com/in/coreymccann/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved